A Phase 1, Multicenter, Open-Label, Dose Escalation Study of ASP3026 in Subjects With Advanced Malignancies

Inclusion Criteria:

- Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2

- Histologically or cytologically confirmed diagnosis of a relapsed/refractory solid
tumor or B-cell lymphoma and meets at least 1 of the following criteria:

- Disease progression despite standard therapies

- No standard therapies are available or such therapies are not anticipated to
result in a durable response

- Standard therapies are considered unsuitable or have been refused

- Able to take oral medications

- Life expectancy > 12 weeks

- For the expansion cohort of the study, all subjects must be confirmed to be positive
for ALK gene abnormalities

- Subjects with stable brain metastasis will be allowed

Exclusion Criteria:

- Active central nervous system (CNS) metastases or leptomeningeal involvement as
assessed through medical history review and physical examination

- Known history of a positive test for hepatitis B surface antigen (HBsAg) or hepatitis
C antibody (anti-HCV)

- Known hereditary or acquired immunodeficiency syndrome or human immunodeficiency
virus (HIV) infection

- Cardiac arrhythmias > Grade 1 using National Cancer Institute Common Terminology
Criteria for Adverse Events (NCI CTCAE) v. 4.03

- Class 3 or 4 New York Heart Association congestive heart failure, acute coronary
syndrome, myocardial infarction or cerebrovascular accident within 6 months prior to
Cycle 1, Day 1

- Inadequate bone marrow, renal, and/or hepatic function

- Confirmed active peptic ulcer disease or history of gastrointestinal bleeding within
the past 3 months

- Known history of long QT syndrome